Embecta, the largest maker of disposable pen needles and insulin syringes for people withy diabetes, has announced plans to develop its own insulin pump, signaling a major shift in its business model.
Embecta (once known as BD) has advanced its pump project by partnering with Tidepool, a nonprofit organization that hosts software for people with diabetes and who received US clearance for a community-developed insulin dosing algorithm earlier this year, making it available for all interoperable hardware.
While Tidepool’s clearance covers the use of the algorithm in the management of Type 1 diabetes, Embecta is targeting the less-penetrated Type 2 insulin pump market and plans to work with Tidepool to develop open- and closed-loop systems.
To read more, CLICK HERE.
